Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma
- PMID: 27984643
- DOI: 10.1111/bjh.14449
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma
Keywords: Hodgkin lymphoma; antibody-drug conjugate; autologous stem cell transplant; monoclonal antibodies; refractory disease.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical